Response to Clozapine in Treatment Resistant Schizophrenia: A Longitudinal Magnetic Resonance Spectroscopy Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

108 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-04-30

Study Completion Date

2022-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the relationship between glutamate and related brain chemicals and treatment response to clozapine in patients with treatment-resistant schizophrenia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

fMRI Cholinergic Mechanisms in Schizophrenia

NCT01191827

Schizophrenia

COMPLETED

The Role of Glutamatergic Function in the Pathophysiology of Treatment-resistant Schizophrenia

NCT06270108

Treatment-resistant Schizophrenia Treatment-responsive Schizophrenia Healthy Controls

RECRUITING EARLY_PHASE1

Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia

NCT01545999

Schizophrenia

ACTIVE_NOT_RECRUITING NA

Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography

NCT00942981

Schizoaffective Disorder Schizophrenia

COMPLETED

Neural Biomarkers of Clozapine Response

NCT03076346

Schizophrenia Treatment-resistant Schizophrenia Schizoaffective Disorder

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will be a prospective proton spectroscopy (1H-MRS) study designed to compare the levels of glutamate, glutamine, glx, and glutathione in age- and gender- matched patients with poor response to clozapine (URS), patients with good response to clozapine (non-URS), and healthy controls. Participants with schizophrenia who fail to respond to optimal treatment with at least two different non-clozapine antipsychotics (i.e. treatment-resistant schizophrenia \[TRS\]) and who are starting clozapine as part of their clinical care will be recruited. A sample of healthy controls will also be recruited. Participants with TRS will have two 1H-MRS scans. The 1H-MRS scan will be performed within 1 week and 12 weeks after clozapine initiation. Clinical assessments will be performed within 1 week of each 1H-MRS scan and after 6 weeks of clozapine treatment. Cognitive assessments will also be performed within 1 week of 1H-MRS scans. Healthy controls will also undergo two 1H-MRS scans with a 12-week interval. Cognitive assessments will also be performed within 1 week of 1H-MRS scans.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Clozapine Responders (Non-URS)

Definition of non-URS

(1) ≥30% decrease in the PANSS positive subscale score, CGI-severity ≤3 and CGI-Improvement ≤2 after 12 weeks of treatment.

Clozapine

Intervention Type DRUG

Patient participants will be starting clozapine as part of their clinical care.

Clozapine Non-Responders (URS)

Definition of URS

1. Taking clozapine for ≥ 12 weeks, attaining a plasma clozapine level ≥350 ng/ml.
2. CGI-Severity score of ≥4 and score of ≥4 on 2 PANSS positivesymptom items.

Clozapine

Intervention Type DRUG

Patient participants will be starting clozapine as part of their clinical care.

Healthy Controls

Healthy controls will be matched as closely as possible on age and gender with participants in the patient groups.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clozapine

Patient participants will be starting clozapine as part of their clinical care.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Clozaril

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* DSM-IV/SCID diagnosis of schizophrenia, schizoaffective disorder, delusional disorder, or psychotic disorder NOS.
* Age 18 years or older at time of scanning
* History of failure to respond to at least two previous sequential antipsychotic treatments different to clozapine, each attaining a chlorpromazine daily dose of≥ 400 mg for a duration ≥ 6 consecutive weeks.Long-acting antipsychotic treatment will not be allowed during the last trial prior to clozapine in order to avoid residual concentrations or effects.Failure of treatment will be defined by a Clinical Global Impression Severity (CGI-Severity) score of ≥4 and score of ≥4 on 2 Positive and Negative Syndrome Scale (PANSS) positive symptom items. The CGI-Severity or Global Assessment of Functioning (GAF) will be completed retrospectively based on information provided by the participant, participant's psychiatrist, medical chart, or other sources of available collateral information.

* Age of 18 and older at time of scanning
* Being capable to consent to study procedures
* Absence of history of psychiatric illness using the Mini-International Neuropsychiatric Interview (MINI)

Exclusion Criteria

* Incapacity to provide consent to participate in the research study.
* Substance abuse or dependence (within past six months), excluding nicotine and caffeine.
* Positive urine drug screen for drugs of abuse.
* Metal implants or a pace-maker that would preclude the MRI scan.
* History of head trauma resulting in loss of consciousness \> 30 minutes that required medical attention.
* Unstable physical illness or significant neurological disorder including a seizure disorder.
* Size of head, neck, and body being unable to fit MRI scanners.
* Refusal to provide consent to investigator to communicate with physician of record to obtain collateral information.
* Psychiatric concerns raised by the physician of record regarding participation in the study.
* Currently taking medications that may directly impact the glutamatergic system (i.e. lamotrigine, topiramate, memantine or N-acetylcysteine)
* ECT, MST or TMS in the past 6 months

* First degree family member with primary psychotic disorder
* Substance abuse or dependence (within past six months), excluding nicotine and caffeine.
* Positive urine drug screen for drugs of abuse
* Pacemakers, metallic cardiac valves, magnetic material such as surgical clips, implanted electronic infusion pumps or any other conditions that would preclude the MRI scan
* Clinically significant claustrophobia
* History of head trauma resulting in loss of consciousness \> 30 minutes that required medical attention
* Size of head, neck, and body being unable to fit MRI scanners
* Unstable physical illness or significant neurological disorder including a seizure disorder

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes